N-[2-(2-chlorophenyl)-4-oxochromen-8-yl]-1,3-thiazole-4-carboxamide | 1219445-79-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: N-[2-(2-chlorophenyl)-4-oxochromen-8-yl]-1,3-thiazole-4-carboxamide
• CAS: 1219445-79-0
• 化学式: C₁₉H₁₁ClN₂O₃S
• 分子量: 382.827
• InChiKey: XWESVNUIXMUZLZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  96.5
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• CHROMENONE ANALOGS AS SIRTUIN MODULATORS
  申请人：Oalmann Christopher

  公开号：US20110257174A1

  公开（公告）日：2011-10-20

  Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了新型的调节sirtuin的化合物及其使用方法。这些sirtuin调节化合物可用于延长细胞寿命，治疗和/或预防各种疾病和障碍，包括与衰老或压力相关的疾病或障碍、糖尿病、肥胖症、神经退行性疾病、心血管疾病、血液凝块障碍、炎症、癌症和/或潮红，以及需要增加线粒体活性的疾病或障碍。还提供了包含sirtuin调节化合物与另一种治疗剂组合的组合物。
• US8987258B2
  申请人：——

  公开号：US8987258B2

  公开（公告）日：2015-03-24
• [EN] CHROMENONE ANALOGS AS SIRTUIN MODULATORS<br/>[FR] ANALOGUES DE CHROMÉNONE EN TANT QUE MODULATEURS DE SIRTUINE
  申请人：SIRTRIS PHARMACEUTICALS INC

  公开号：WO2010037127A1

  公开（公告）日：2010-04-01

  Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.